iRhythm Technologies, Inc. (IRTC)

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

• 年次報告書（10-K）

  事業内容、財務実績、リスクをまとめた年次の概要。

  提出日: 2026-02-19

  書類を見る

• 四半期報告書（10-Q）

  直近3か月間の業績に関する最新情報。

  提出日: 2026-08-06

  書類を見る

• 臨時報告書（8-K）

  経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

  提出日: 2026-09-22

  書類を見る

• 3d agoPOSITIVE
  JP Morgan forecasts a 20x revenue increase for this AI stock

  JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.

• 6/16/2026NEGATIVE
  iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data

  iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.